The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC) has issued the following new and updated documents, which were adopted by NHF’s Board of Directors on October 6, 2013:

MASAC Document #218

MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders (Revised October 2013)

MASAC Document #219

MASAC Resolution on Need to Facilitate Dialogue Between HTCs and Payers to Improve Access to Care at HTCs

MASAC Document #220

MASAC Recommendation Regarding Prophylaxis with Bypassing Agents in Patients with Hemophilia and High Titer Inhibitors

MASAC Document #221

MASAC Recommendations on Administration of Vaccines to Individuals with Bleeding Disorders

MASAC Document #222

MASAC Recommendations Regarding Physical Therapy Guidelines in Patients with Bleeding Disorders (Revised October 2013)

MASAC Document #223

MASAC Recommendations on Liver Biopsy in Individuals with Hemophilia

(Revised October 2013)

To view these documents, click the corresponding links above or review the complete list of current MASAC documents. To request a hard copy of any current documents, please contact HANDI, NHF’s information resource center: handi@hemophilia.org or 1.800.424.2634